New data from Fasenra and Tezspire trials demonstrate AstraZeneca biologics progress towards achieving remission in severe asthma New EXACOS-CV data uncover increased cardiopulmonary risk following COPD exacerbations London – AstraZeneca will present new clinical and real-world data across its leading inhaled, biologic and early science respiratory portfolio at the European Respiratory Society (ERS) International Congress 2023, in Milan, Italy from …
KIRKLAND – Rethink Breast Cancer (Rethink) and Pfizer Canada are proud to announce three recipients who will collectively receive over $200,000 in grants for their work in developing innovative strategies to measurably improve the quality of care for people living with metastatic breast cancer (mBC). Guided by the unique and unmet needs identified by people living with mBC and their families, …
Symptoms of polio Canada – Polio (poliomyelitis) is a highly infectious vaccine-preventable disease that is caused by the poliovirus. Most people who are infected with poliovirus don’t have any symptoms. Those who get symptoms at first may experience: fever sore throat headache abdominal pain nausea vomiting tiredness loss of appetite aching muscles stiff neck or back Typically, symptoms last between 2 …
London – Soliris (eculizumab) has been approved in Japan for expanded use to include the treatment of generalised myasthenia gravis (gMG) in paediatric patients who are anti-acetylcholine receptor (AChR) antibody-positive and whose symptoms are difficult to control with high-dose intravenous immunoglobulin (IVIG) therapy or plasmapheresis (PLEX). Soliris is the first and only targeted therapy approved for the treatment of children and adolescents with gMG …
Washington – Scientists at City of Hope, a leading US hospital and one of the largest cancer research and treatment organisation in the country, have developed a “cancer-killing pill”that kills solid tumours through “targeted chemotherapy.” They said: “As snowstorm closes a key airline hub, shutting down all flights in and out only in planes carrying cancer cells,” this pill does that. …
Washington – There are no shortcuts when developing safe and effective medicines. On average, it can take 10-15 years to bring a new medicine from early-stage research through clinical trials. The reality is, despite recent scientific advances, there are many serious and life-threatening diseases that lack meaningful treatments, therapies, or cures. Waiting a decade could be the difference between life …
Ottawa – The Patented Medicine Prices Review Board (PMPRB) published today the 7th edition of its annual Meds Entry Watch report. The analysis finds that the number of new medicines launched in Canada is higher than the median for Organisation for Economic Co-operation and Development (OECD) countries but falls below the median of the eleven PMPRB comparators, all of which have lower average …
AstraZeneca will present 19 abstracts, including 10 oral presentations and five late-breaking presentations, at the European Society of Cardiology (ESC) Congress from 25-28 August 2023, which includes data highlighting the opportunities for improved management in heart failure (HF), and AstraZeneca’s leadership across the interconnectedness of chronic diseases. Among these abstracts will be sub-analyses from the DELIVER trial – a trial …
Ottawa – Novo Nordisk spokesperson Kate Hanna in an emailed statement that they are “experiencing a temporary supply disruption with the Ozempic 1 mg (injection) pen due to the combination of overall global supply constraints coupled with increased demand.” The 0.25 mg and 0.5 mg doses of Ozempic injection pens remain available “for patients with Type 2 diabetes across Canada,” …
Submitting applications and documentation during COVID-19 Due to COVID-19, the Ontario Drug Benefit Program has implemented temporary processes to apply for the Trillium Drug Program and the Seniors Co-Payment Program. Trillium Drug Program (TDP) application To submit a Trillium Drug Program application or supporting documentation, you can either: fax the documents to 416-642-3034 e-mail the documents to trillium@ontariodrugbenefit.ca If faxing or emailing, you …
